{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:43:54Z","timestamp":1793245434648,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment with eculizumab in Shiga toxin\u2013associated haemolytic and uraemic syndrome (STEC-HUS) remains controversial despite its increasing utilization. The aim of our study was to evaluate the outcomes of children treated with eculizumab for STEC-HUS in a single-centre matched cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were retrospectively collected from medical records of children diagnosed with STEC-HUS. The outcomes of patients treated with eculizumab for STEC-HUS were compared with those of a control group of untreated patients matched for age, sex and severity of acute kidney injury with a 1:2 matching scheme.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighteen children (median age 40.6\u2009months) with STEC-HUS treated with eculizumab were compared with 36 matched control patients (median age 36.4\u2009months) who did not receive eculizumab. All patients survived in the two groups. Within 1\u2009month of HUS onset, the evolution of haematological and renal parameters did not differ between the two groups. At 12\u2009months of follow-up, renal outcome was not significantly different between the two groups. At the last follow-up, the prevalence of decreased glomerular filtration rate in the eculizumab group (27%) was not statistically different from that in controls (38%), as was the prevalence of proteinuria and high blood pressure. Children who received eculizumab more often had extrarenal sequelae during follow-up. Eculizumab treatment appeared to be safe in children with STEC-HUS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The benefit of eculizumab on renal and extrarenal outcomes in STEC-HUS could not be established based on our findings. However, efficacy and safety are not best assessed by the observational design and small sample size of our study. Randomized controlled trials are thus required to determine the efficacy of eculizumab in this indication.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ndt\/gfz158","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:10:11Z","timestamp":1562843411000},"page":"2147-2153","source":"Crossref","is-referenced-by-count":23,"title":["Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study"],"prefix":"10.1093","volume":"35","author":[{"given":"Catherine","family":"Monet-Didailler","sequence":"first","affiliation":[{"name":"Service de P\u00e9diatrie, Unit\u00e9 de N\u00e9phrologie, Centre de r\u00e9f\u00e9rence Maladies R\u00e9nales Rares du Sud-ouest, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Chevallier","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie, Unit\u00e9 de N\u00e9phrologie, Centre de r\u00e9f\u00e9rence Maladies R\u00e9nales Rares du Sud-ouest, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Godron-Dubrasquet","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie, Unit\u00e9 de N\u00e9phrologie, Centre de r\u00e9f\u00e9rence Maladies R\u00e9nales Rares du Sud-ouest, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Allard","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie, Unit\u00e9 de N\u00e9phrologie, Centre de r\u00e9f\u00e9rence Maladies R\u00e9nales Rares du Sud-ouest, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahsou","family":"Delmas","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Centre de r\u00e9f\u00e9rence Maladies R\u00e9nales Rares du Sud-ouest, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Contin-Bordes","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019Immunologie et Immunog\u00e9n\u00e9tique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Brissaud","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation P\u00e9diatrique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Llanas","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie, Unit\u00e9 de N\u00e9phrologie, Centre de r\u00e9f\u00e9rence Maladies R\u00e9nales Rares du Sud-ouest, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Harambat","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie, Unit\u00e9 de N\u00e9phrologie, Centre de r\u00e9f\u00e9rence Maladies R\u00e9nales Rares du Sud-ouest, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"},{"name":"Universit\u00e9 de Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"2020120410271653500_gfz158-B1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"2020120410271653500_gfz158-B2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nrneph.2012.196","article-title":"Renal and neurological involvement in typical Shiga toxin-associated HUS","volume":"8","author":"Trachtman","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2020120410271653500_gfz158-B3","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","article-title":"Long-term outcomes of Shiga toxin hemolytic uremic syndrome","volume":"28","author":"Spinale","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"2020120410271653500_gfz158-B4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/cis196","article-title":"Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late emerging sequelae","volume":"54","author":"Rosales","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020120410271653500_gfz158-B5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00467-018-4131-z","article-title":"Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort","volume":"34","author":"Monet-Didailler","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2020120410271653500_gfz158-B6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"2020120410271653500_gfz158-B7","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"2020120410271653500_gfz158-B8","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J Immunol"},{"key":"2020120410271653500_gfz158-B9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shigatoxin promotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol"},{"key":"2020120410271653500_gfz158-B10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2020120410271653500_gfz158-B11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.kint.2016.07.002","article-title":"Complement contributes to the pathogenesis of Shigatoxin-associated hemolytic uremic syndrome","volume":"90","author":"Karpman","year":"2016","journal-title":"Kidney Int"},{"key":"2020120410271653500_gfz158-B12","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"2020120410271653500_gfz158-B13","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2020120410271653500_gfz158-B14","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"2020120410271653500_gfz158-B15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/cid\/cis531","article-title":"An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children","volume":"55","author":"Loos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020120410271653500_gfz158-B16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/cix218","article-title":"Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011outbreak caused by E. coli O104:H4","volume":"64","author":"Loos","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020120410271653500_gfz158-B17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2020120410271653500_gfz158-B18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00431-017-3077-7","article-title":"Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence","volume":"177","author":"Keenswijk","year":"2018","journal-title":"Eur J Pediatr"},{"issue":"2 Suppl 1","key":"2020120410271653500_gfz158-B19","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney"},{"key":"2020120410271653500_gfz158-B20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2020120410271653500_gfz158-B21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"MAbs"},{"key":"2020120410271653500_gfz158-B22","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","article-title":"Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement","volume":"94","author":"Pape","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2020120410271653500_gfz158-B23","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","article-title":"Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study","volume":"33","author":"Percheron","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2020120410271653500_gfz158-B24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0009922814534520","article-title":"Response to eculizumab in Escherichia coli O157:H7-induced hemolytic uremic syndrome with severe neurological manifestations","volume":"54","author":"Saini","year":"2015","journal-title":"Clin Pediatr (Phila)"},{"key":"2020120410271653500_gfz158-B25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/dmcn.12161","article-title":"Brain magnetic resonance imaging pattern and outcome in children with haemolytic uraemic syndrome and neurological impairment treated with eculizumab","volume":"55","author":"Gitiaux","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"2020120410271653500_gfz158-B26","first-page":"246","article-title":"Hemolytic uremic syndrome outbreak in Turkey in 2011","volume":"55","author":"Ekinci","year":"2013","journal-title":"Turk J Pediatr"},{"key":"2020120410271653500_gfz158-B27","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2215\/CJN.08921209","article-title":"Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome","volume":"5","author":"Nathanson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020120410271653500_gfz158-B28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00467-018-4112-2","article-title":"A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement","volume":"34","author":"Giordano","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2020120410271653500_gfz158-B29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00467-018-4025-0","article-title":"Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome","volume":"34","author":"Walsh","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2020120410271653500_gfz158-B30","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00467-018-3972-9","article-title":"Eculizumab in STEC-HUS: need for a proper randomized controlled trial","volume":"33","author":"Loos","year":"2018","journal-title":"Pediatr Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/12\/2147\/34696736\/gfz158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/12\/2147\/34696736\/gfz158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T21:41:38Z","timestamp":1721511698000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/35\/12\/2147\/5549859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,8,14]]},"published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz158","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2019,8,14]]}}}